The Metabolic Tests Behind Cancer Risk, Progression, and Recurrence

If you have been following the latest breakthroughs in cancer prevention and metabolic health, you have likely encountered a sobering reality: conditions like insulin resistance, hyperinsulinemia, prediabetes, and metabolic syndrome are not merely passive risk factors. They are active, modifiable drivers of some of cancer’s most dangerous features. Research published as recently as 2025 and 2026 has cemented this link, showing that these metabolic dysfunctions can actually ignite cancer formation, fuel its aggressive spread, undermine the effectiveness of treatments, and dramatically increase the odds of recurrence. Understanding this connection is the first step toward taking meaningful action, but to do so, we must look beyond the standard, often inadequate, tests offered in routine checkups.

The Cancer-Metabolism Connection: What the Latest Science Reveals

To grasp the urgency, consider what happens inside your body when insulin resistance takes hold. Your cells become less responsive to insulin, so your pancreas compensates by pumping out ever-higher amounts of this hormone. The resulting state, known as hyperinsulinemia, is now understood by scientists as a potential carcinogenic priming event. Chronically high insulin levels not only regulate blood sugar; they also directly activate powerful pro-growth signaling pathways within cells, namely the PI3K/AKT/mTOR and MAPK/ERK cascades. These pathways are the very same ones that drive cellular proliferation and inhibit apoptosis, the natural process of programmed cell death that normally eliminates damaged cells before they can turn cancerous.

The research shows that cancer risk increases by a staggering twenty-five to two hundred and fifty percent in people with prediabetes alone, with particular danger for pancreatic, liver, colorectal, endometrial, and breast cancers. This is not a distant concern; cancer may already be brewing silently alongside the earliest stages of glucose dysregulation. An independent association between insulin resistance and cancer has been consistently reported, with this metabolic adaptation often preceding the clinical diagnosis of cancer. The connection between prediabetes and pancreatic cancer risk has been particularly well-documented, with prediabetes remission potentially modifying this risk. Lower glycemic status has been specifically associated with pancreatic cancer risk in prediabetes, though not necessarily in diabetes. A meta-analysis has also confirmed the association between prediabetes and thyroid cancer risk. The link between insulin resistance and early-onset colorectal cancer is increasingly recognized.

How Metabolic Dysfunction Fuels Tumor Growth and Spread

Once a tumor has established itself, a background of insulin resistance and metabolic syndrome creates an almost perfect environment for it to thrive. The chronic hyperinsulinemia and elevated blood sugar foster a tumor-favorable microenvironment, one that actively encourages cancer cells to migrate, invade surrounding tissues, and ultimately metastasize to distant organs. Chronic elevations in glucose and insulin levels accelerate cancer cell proliferation, survival, migration, and angiogenesis. A 2025 study demonstrated that insulin resistance increases the aggressiveness of triple-negative breast cancer and promotes brain metastasis through adipocyte-derived exosomes. Patients with this aggressive breast cancer subtype and comorbid type 2 diabetes have a higher risk of metastasis and shorter survival.

The overactivation of the PI3K and MAPK pathways, driven by excess insulin, is directly responsible for this enhanced aggressiveness. These pathways fuel tumor growth by supporting the metabolic reprogramming that cancer cells depend on for survival, rapid growth, and metastasis. The role of metabolic inflammation in obesity-associated carcinogenesis is also critical. Insulin resistance and metabolic dysfunction have also been implicated in thyroid nodule growth and tumorigenesis. Diabetogenic processes for insulin resistance-linked hyperinsulinemia have been associated with colorectal cancer.

Treatment Resistance: When Metabolism Undermines Therapy

The threat does not end with progression; these metabolic derangements actively sabotage cancer treatment. Hyperglycemia and hyperinsulinemia promote chemoresistance and apoptosis resistance in cancer cells, making it harder for standard therapies to work. Research has shown that high glucose levels promote cisplatin chemoresistance in breast cancer cells, while hyperinsulinemia activates those same survival pathways, PI3K and MAPK, to confer resistance in various tumors. In melanoma, insulin attenuates the therapeutic efficacy of standard treatments by activating the PI3K/Akt pathway.

The role of metabolic reprogramming in driving therapy resistance is particularly evident in ovarian cancer, where it has emerged as a key factor driving tumor progression, therapy resistance, and poor clinical outcomes. Metabolic syndrome has also been linked to treatment resistance in gastric cardia adenocarcinoma through signaling pathways involving immune checkpoint inhibitors. Patients with co-morbid type 2 diabetes experience faster biochemical recurrence and increased mortality from prostate cancer. The effects of T2DM on cancer progression involve pivotal precipitating factors and underlying mechanisms that undermine treatment efficacy.

The Recurrence Risk: A Persistent Threat

Perhaps most alarmingly, metabolic dysfunction is strongly tied to cancer recurrence. A comprehensive systematic review and meta-analysis published in 2025 found that breast cancer survivors who had metabolic syndrome at the time of their diagnosis experienced a significantly increased risk of recurrence and breast cancer mortality. Survivors with metabolic syndrome experience a higher incidence of breast cancer recurrence through mechanisms such as obesity, physical inactivity, hyperinsulinemia, and insulin resistance.

The link extends to other cancer types as well. In elderly patients with hepatocellular carcinoma, the five-year recurrence rate was notably higher among those with metabolic syndrome compared to those without, and mortality risk escalated as the number of metabolic syndrome components increased. Metabolic syndrome combined with insulin resistance has shown great predictive value in evaluating recurrence in patients with atypical endometrial hyperplasia and early endometrial cancer. In colorectal cancer, metabolic syndrome is associated with increased risk of recurrence and reduced overall and disease-free survival.

A real-world cohort study of over seven thousand cancer patients published in 2025 found that those who developed new-onset prediabetes or diabetes after their cancer diagnosis had significantly worse overall survival. The study also shed light on the importance of management: metformin use was associated with much better survival, while insulin use was paradoxically linked to worse outcomes, underscoring the complex interplay between these interventions and cancer biology. Trajectories of type 2 diabetes and cancer in hundreds of thousands of individuals with prediabetes have been examined in a twenty-year observational study in England, further confirming these associations. The energy model of insulin resistance provides a unifying theory linking metabolic dysfunction to cancer.

The Foundation: Essential Blood Tests Your Doctor Should Order

Given these profound connections, it becomes clear that a thorough assessment of your metabolic health is not an optional luxury; it is a critical component of cancer prevention and long-term survivorship. However, the standard panel of tests offered at most annual physicals is woefully inadequate to catch these issues early. You can have significant insulin resistance for years while your fasting glucose and hemoglobin A1c remain entirely normal, because your pancreas is working overtime to compensate, driving your insulin levels dangerously high while masking the problem on standard sugar tests.

The foundation of any thorough assessment begins with essential bloodwork. Your doctor should order a fasting plasma glucose test and a hemoglobin A1c to establish your baseline blood sugar control. But the most critical, and most frequently omitted, test is a fasting insulin level. Without this, you are effectively flying blind. By combining your fasting insulin and fasting glucose, your doctor can calculate a score known as HOMA-IR. A HOMA-IR value above two and a half to three is a strong indicator of insulin resistance, regardless of whether your sugar levels look pristine.

Additionally, a fasting lipid panel is indispensable because metabolic syndrome is defined by specific derangements in your fats, particularly high triglycerides of 150 milligrams per deciliter or higher and low HDL, the good cholesterol, below 40 for men or below 50 for women. These lipid markers, along with blood pressure readings above 130/85 and a waist circumference over 40 inches for men or 35 inches for women, form the diagnostic criteria for metabolic syndrome. According to the National Institutes of Health, having three or more of these five conditions confirms the diagnosis. Associations between four insulin resistance surrogates and the risk of small cell lung cancer have also been identified, further emphasizing the importance of these markers. A meta-analysis has confirmed the increased colorectal cancer risk in prediabetes.

Advanced Blood Markers for a Deeper Look

For a deeper dive into your metabolic health, consider advanced blood markers that go beyond the basics. A comprehensive metabolic panel checks your liver and kidney function, which can reveal early signs of non-alcoholic fatty liver disease, a close cousin of insulin resistance. A C-peptide test provides a more stable and accurate picture of your pancreas’s average insulin output over time, complementing the snapshot of a fasting insulin level.

Apolipoprotein B is a more precise marker of harmful cholesterol particles than LDL alone and is strongly associated with insulin resistance. High-sensitivity C-reactive protein measures systemic inflammation, a hallmark of metabolic syndrome, while uric acid levels are often elevated in this condition. Sex hormone-binding globulin, when low, is also a telltale sign of insulin resistance, particularly relevant for women with polycystic ovary syndrome. These markers help paint a complete picture of the inflammatory and metabolic milieu inside your body.

One particularly valuable, but often overlooked, advanced test is 1,5-anhydroglucitol. Unlike fasting glucose, which is a static snapshot, or hemoglobin A1c, which is a 2-3-month average, 1,5-anhydroglucitol specifically detects dangerous post-meal glucose spikes exceeding 180 mg/dL over the previous 1 to 2 weeks. This is crucial because these sudden surges after eating can wreak havoc even when your other tests look normal. A low 1,5-anhydroglucitol level is a direct indicator of significant recent hyperglycemia, making it an excellent tool for uncovering hidden glycemic instability. However, it is not a diagnostic test for prediabetes itself; its strength lies in revealing the severity of post-meal excursions, which are a major driver of the cardiovascular and inflammatory damage linked to insulin resistance. It is best reserved for those with borderline results, strong family histories, or symptoms of post-meal fatigue and brain fog.

The Game-Changer: One Month with a Continuous Glucose Monitor

If you truly want to understand your metabolic health in real time, there is no tool more powerful than a one-month continuous glucose monitor (CGM). A CGM is a small sensor worn on the arm that tracks your glucose twenty-four hours a day, providing a dynamic movie of your metabolism rather than the static snapshot offered by blood tests. This device reveals exactly what happens after you eat, showing you how your body responds to specific foods, exercise, stress, and sleep.

Recent research highlights that in people with prediabetes or normal blood sugar, the metrics derived from a CGM have only a weak to minimal association with hemoglobin A1c, meaning two people with the same average glucose can have wildly different daily spikes and valleys, and thus very different metabolic risks. A one-month trial provides enough data to identify persistent patterns while remaining practical and actionable. During this time, you can personally test the impact of a morning walk versus an evening walk, see the consequences of a poor night’s sleep, and discover which carbohydrate sources your body handles best.

Perhaps the most cutting-edge aspect of CGM technology is its ability to help identify your specific metabolic subphenotype. Scientists now know that prediabetes is characterized by metabolic heterogeneity, meaning insulin resistance can look very different from person to person. Using machine learning, researchers can now interpret your CGM data to determine whether your primary issue is muscle insulin resistance, where your muscles fail to efficiently take up glucose; hepatic insulin resistance, where your liver overproduces glucose; or beta-cell dysfunction, where your pancreas cannot keep up with insulin demand. Knowing this distinction is transformative because it allows for truly personalized interventions. For instance, muscle insulin resistance may respond better to a targeted exercise regimen, while hepatic resistance might require a different dietary approach. This level of precision is simply impossible to achieve with standard blood tests alone.

Putting It All Together: Your Roadmap to Empowerment

Equipped with this comprehensive knowledge, you are no longer guessing about your health. You move from a passive recipient of test results to an empowered individual who understands the intricate connections between your metabolism and your long-term cancer risk. Armed with fasting insulin, HOMA-IR, advanced inflammatory and lipid markers, and the dynamic feedback from a CGM, you can work with your healthcare provider to implement precise dietary changes, exercise strategies, and potentially medication adjustments, such as metformin, which has shown protective benefits in cancer outcomes.

The evidence is clear that early intervention for newly diagnosed prediabetes, especially within the first three years of a cancer diagnosis, may be critical for improving survival. By demanding a thorough metabolic workup, you are taking a proactive stand against one of the most significant, yet modifiable, drivers of cancer initiation, progression, treatment resistance, and recurrence. This is not just about managing numbers on a chart; it is about reclaiming control over your biological destiny.

References

The Metabolic Tests Behind Cancer Risk, Progression, and Recurrence

Dr. Daniel Thomas, DO, MS